Objectives The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation. Because NOACs have
significant renal clearance, dose reduction is needed in patients with severe kidney disease.
However, some physicians may prescribe reduced-dose NOACs to patients with relatively
good renal function due to the concerns over the bleeding risk. We sought to investigate the
use and clinical outcomes of reduced-dose NOACs in patients without severe renal …

Objective To examine clinical effectiveness and safety of apixaban 2.5 mg, dabigatran 110
mg, and rivaroxaban 15 mg compared with warfarin among patients with atrial fibrillation
who had not previously taken an oral anticoagulant. Design Propensity weighted (inverse
probability of treatment weighted) nationwide cohort study. Setting Individual linked data
from three nationwide registries in Denmark. Participants Patients with non-valvular atrial
fibrillation filling a first prescription for an oral anticoagulant from August 2011 to February …